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Summary As part of a Phase I clinical trial, 5 patients received 5-fluorouracil (FU) both singly and in
combination with misonidazole (MISO) for the treatment of gastrointestinal cancer. Concentrations of total
FU and F-containing metabolites in urine specimens, taken during 48h after therapy, were determined. The
clearance of FU following administration of 1.0 or 1.5g FU m-2 was significantly reduced by treatment with
MISO (1.75-2.0gm2) given 2h prior to FU therapy. Reduced clearance of FU by MISO was associated
with an earlier onset of the period of nonlinearity of FU pharmacokinetics and an increased half-life of
elimination. Furthermore, the clearance of FU correlated inversely with the severity of gastrointestinal
toxicity. The mechanism of MISO enhancement of FU action is unlikely to be competition for microsomal
enzymes, as proposed for the interaction of MISO and alkylating agents, since FU is catabolized at
mitochondrial and cytosolic sites.
There is considerable evidence from in vitro and in
vivo studies in animals to suggest that the 2-
nitroimidazole, misonidazole (MISO), a
radiosensitizer of hypoxic cells, enhances tumour
response to chemotherapy (reviews by McNally,
1982; Millar, 1982; Siemann, 1982a). The
potentiation mechanism, however, is unclear
(reviewed by Brown, 1982) and clinical studies
(Spooner et al., 1982; Urtasun et al., 1982) are
limited.
Administration of MISO simultaneously with 5-
fluorouracil (FU) in mice bearing Lewis lung
carcinoma enhanced the tumour response assessed
by clonogenic cell survival (Stephens et al., 1981).
FU-induced growth delay of the 16/C mammary
carcinoma and the KHT sarcoma was increased by
the addition of MISO (Tannock, 1980a). Host
toxicity, measured by death and loss of body
weight, however, was also increased, resulting in
only a small gain in therapeutic index.
Since the enhancement of effect by MISO occurs
with cytotoxic drugs of diverse mechanisms of
action, Stephens et al. (1981) suggested that MISO
may alter drug pharmacokinetics, leading to greater
exposure to the drug. In animal studies, MISO has
been shown to alter the pharmacokinetics of
alkylating agents (Tannock, 1980b; Stephens et al.,
1981; Clutterbuck et al., 1982; Workman et al.,
1983) and nitrosoureas (Tannock, 1980b; Lee &
Workman, 1983), but the effect of the sensitizer on
drug elimination in humans has not been reported.
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This paper describes a preliminary study of the
pharmacokinetics of FU and of FU with
concurrent administration of MISO for
gastrointestinal cancer as part of a Phase I clinical
trial.
Materials and methods
Patients andprotocols
Five patients with advanced gastrointestinal cancer
(Table I) participated with informed consent.
Subjects were evaluated by clinical examination,
biochemical tests for liver, renal and haematological
function, chest and skeletal radiography and
radioisotope scans. Patients received: FU
(1.0gm-2); MISO (1.75 or 2.0gm-2) and FU
(l.Ogm-2); FU (1.5gm-2); MISO (1.75 or
Table I Patient protocols
Surface area
PatientSexAge (m2) Disease status
R.C. M 42 1.7 Carcinoma of rectum,
resected; lung metastases
J.K. M 61 1.7 Carcinoma ofcolon, liver
metastases
M.P. F 72 1.3 Carcinoma of
rectosigmoid, peri-anal
recurrence
S.A. F 70 1.5 Carcinoma of sigmoid
colon, local recurrence
R.J. M 68 1.8 Carcinoma ofcaecum,
resected; small liver
metastases
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2.0gm-2) and FU (.5gm-2); consecutively. Each
course of MISO and FU was administered 3-5
weeks after the corresponding treatment with FU
alone. MISO was administered orally 2h before
FU, which was given by i.v. injection. Patients were
questioned regarding possible side-effects, in
particular, nausea and vomiting, alopecia and
neuropathy. Sodium azide (1 g -1) was used as
preservative for urine specimens which were
collected as voided spontaneously, before therapy
and at timed intervals up to 48h after treatment.
The volumes of specimens were recorded and
aliquots (25ml) were stored at -20°C.
Analysis
Total FU and F-containing metabolites were
estimated in urine using a F-specific electrode after
combustion of specimens in an oxygen flask
(McDermott et al., 1982). Analytical recovery of
the method was 99.5% and 96.3%. and intra-assay
variation (s.e.) was 2.5% (n=8) and 2.1% (n= 12)
for FU concentrations of 2.0 x 10-5M and
9.0 x 10-4M, respectively. Inter-assay variation
(s.e.) for analysis of 9.0 x 10-4M FU was 3.3%
(n=8).
The time courses of total levels of drug (i.e. drug
plus metabolites) were evaluated by the "Sigma-
minus" method (Wagner, 1963), which consists of
plotting the logarithm of (Xu'-Xu') against time, t,
where (Xu -Xut) represents the sum of the
amounts of total drug excreted until excretion may
be considered to be complete minus the cumulative
amount of drug excreted to t. The data are
presented as % dose excreted remaining in the
body to t, i.e. log (Xu'-Xut) x 100/Xu'. Profiles of
total drug concentrations can be used to obtain
pharmacokinetic parameters of it is assumed that
the rate constants of elimination for all primary
metabolites are appreciably greater than the rate
constant (f) for elimination of the parent drug
(Gibaldi & Perrier, 1975). When drug elimination
occurs by first-order processes, the "Sigma-minus"
plot is linear with slope, -fl/2.303. Half-lives of FU
elimination (t4) were estimated from the initial
apparently linear portions of the plots and were
calculated as 0.693/fl. The areas under "Sigma-
minus" curves (AUC) were determined using the
trapezoid rule (Gibaldi & Perrier, 1975).
Statistical variations were expressed as standard
errors of the mean (s.e.) and comparisons were
made using the Student's t-test for paired samples.
Results
The elimination of total drug for each patient after
the administration of different dosages of FU alone
and of FU with MISO is shown in Figure 1 a-e.
The pharmacokinetic profiles are composed of
linear and nonlinear kinetics as demonstrated
previously for the elimination of FU in patients
receiving therapeutic doses for breast cancer
(McDermott et al., 1982). After administration of
1.0g FUm-2, enhancement of the extent of
saturation of drug elimination by MISO was
particularly noticeable in 3 patients (Figure 1 a, d,
e) but an opposite effect was also observed (Figure
ic). MISO amplified the nonlinearity of FU
elimination kinetics in 2 patients given 1.5g
FUm 2 (Figure 1 c, e).
Figure 2 shows the kinetic characteristics of the
elimination profiles in terms of AUC values and the
percentages of total dose excreted in 48h. MISO
had a potentiating effect on the amount of drug
remaining in the body in 9/10 courses of treatment
investigated (Figure 2). Prior administration of
MISO with FU doses of 1.0 or 1.5gm 2 led to
mean increases in AUC of 91.5+31.1 (s.e.) %h-1
and 103.4+37.5 (s.e.) % x h, respectively, which
were significant (P<0.05). The delayed clearance of
FU from the body in the presence of MISO was
reflected in a reduced extent of urinary excretion of
total drug by only 1 patient after dosage of 1.0g
FUm 2 but by all patients given 1.5gFUm-2. The
average reduction in the excretion of the higher
dosage of FU was 20.4+6.8 (s.e.) %, which was
significant (P<0.05). t4 value of drug elimination
increased when MISO was administered with FU at
both levels of dosage and the average t. values was
greater after FU dosage of 1.5gm 2 than of
1.0gm-2 (Table II), but these results were not
statistically significant.
No toxic effects were evident after therapy with
FU doses of 1.Ogm-2. Gastrointestinal symptoms
were the most common sign of toxicity and these
occurred during 8 of the treatments with the higher
dosage of FU or with the combined MISO and FU
therapy. MISO potentiated the severity of side-
effects during 5 courses of therapy. Table III shows
the relationship between the degree of gastro-
intestinal disturbance and FU clearance. Patient
R.J. had the highest AUC value, after
Table II t. values for the elimination ofdifferent dosages
of FU, with and without MISO
t*(h)
(mean* +s.e.)
FU (1.Ogm-2) 2.84+0.38
FU (1.0gm-2)+MISO 3.30+0.40
FU (1.Sgm-2) 3.70+0.21
FU (1.5gm-2)+MISO 4.32+0.54
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Figure 1 "Sigma-minus" plots of total drug excreted after administration of 1.0mg FUM-2 (circles) and
1.5mgFUm-2 (squares) alone (open symbols) or in conjunction with MISO (closed symbols) o patients (a)
R.C. (b) J.K. (c) M.P. (d) S.A. and (e) R.J.
administration of FU (1.5gm2) with MISO
(2.0gm-2). In addition to experiencing the most
severe gastrointestinal upset, this patient suffered
alopecia and slight neuropathy.
Table III Incidence ofgastrointestinal toxicity
No. of Gastrointestinal Mean AUC value
treatments symptoms [range] (%h-1)
12 None 495 (375-648]
Anorexia,
3 mild nausea 560 [471-682]
Severe nausea,
4 some vomiting 712 [625-796]
1 Severe vomiting 892
Discussion
The hypothesis that the enhancemnent by nitro-
imidazole radiosensitizers of tumo-ar response to
chemotherapeutic agents is mainly a result of
alterations in drug pharmacokinetics has been
proposed by some authors (Tannock, 1980b;
Stephens et al., 1981; Clutterbuck et al., 1982;
Workman & Twentyman, 1982; Lee & Workman,
1983; Workman et al., 1983) but questioned by
others (Martin et al., 1981; Hirst et al., 1982;
Mulcahy et al., 1982; Murray & Meyn, 1983). The
doses of MISO used in experimental studies
generally produce peak plasma levels of MISO 5 to
10 times greater than can be achieved in humans
(reviewed by Workman, 1980). The plasma tj of
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Figure 2 Clearance parameters of total drug after administration of FU alone (El) and in combination with
MISO (a). The values included in the upper diagram represent the % increases in AUC produced by the
addition of MISO to FU treatment. Normal ranges of creatinine clearance (C.C.): males, 85-120mlmin- 1;
females, 75-115mlmin-'.
MISO in man, however, is 10-20 times greater than
in the mouse (Workman, 1980). By administering
multiple small doses of MISO to mice to produce
the prolonged low concentrations that can be
achieved safely in man, enhancement of the tumour
cytotoxicity of alkylating agents has been
demonstrated (Brown & Hirst, 1982; Twentyman &
Workman, 1983).
The findings of the present study are an initial
indication that MISO may influence drug response
in man and that the interaction has a
pharmacokinetic basis. MISO produced
enhancement of AUC values from 2-33% of those
observed when FU was administered alone, during
all but one treatment (Figure 2). The sensitizer
amplified the extent of saturations of FU
elimination during 5 courses of treatment (Figure
1). The failure to observe changes in the shape of
some of the "Sigma-minus" curves with MISO
therapy could be explained by the fact that
increases in AUC of these semilogarithmic plots are
less apparent as the extent of saturated elimination
increases. As a result of increased saturation at the
higher dosage of FU (1.5gm-2), there was a
significant reduction in excretion of total drug by
MISO (Figure 2), but this was less apparent at the
lower dosage (1.0gm-2). Also, there was a
tendency for the apparent ti values to increase as a
consequence of earlier onset of nonlinear
pharmacokinetics with increased dosage of FU
and/or the addition of MISO (Table II), although
these changes were not statistically significant.
The anomalous values of excretion parameters
(Figure 2) may be consequences of changes in
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clinical condition. The increased excretion by
Patient R.C. at the lower dosage of FU with MISO
correlated with an abnormally high value of
creatinine clearance on the day of therapy. The
limited extent of urinary excretion of total drug by
Patient J.K. may be a result of secondary disease in
the liver. In addition, increasingly efficient
catabolism associated with reduction of the volume
of liver metastases could account for the decreased
AUC with escalation of FU dose given alone and
the reduction in AUC in the presence of MISO at
the higher FU dosage.
Clearance of FU correlated inversely with the
degree of gastrointestinal side-effects (Table III),
which were potentiated by MISO in 50% of cases.
However, the toxicity to normal tissues was mild,
compared with other standard regimes of cytotoxic
therapy. Only Patient R.C. with pulmonary
metastases had a measurable lesion, but the
metastases did not respond to FU, at either dose or
with MISO. Two patients, S.A. and M.P., received
local radiotherapy concomitantly with cytotoxic
drugs and the remaining 2 patients, J.K. and R.J.,
had intra-abdominal tumours, which were not
measurable clinically.
The mechanisms by which MISO may alter the
disposition of chemotherapeutic agents is not well
understood. The potentiating effect of MISO may
be a consequence of competition for catabolic sites
with other drugs which are metabolized by
microsomal oxidation (Workman & Twentyman,
1982; Siemann, 1983; Workman et al., 1983) but
there are conflicting results (Law et al., 1981;
Siemann, 1982b). The present study shows that
modulation of the pharmacokinetics of cytotoxic
drugs by MISO cannot be simply competition for
microsomal enzymes, since FU is catabolized at
mitochondrial and cytosolic locations (Wasternak,
1979). Clearance values of FU and its primary
catabolite, 5'6'-dihydro-5-fluorouracil (DHFU),
derived from their concentrations in plasma showed
that saturated elimination could be observed within
6h of drug administration (McDermott et al.,
1982). These data suggested that the initial
catabolic step of FU degradation was saturable.
Preliminary results of the influence of MISO on
plasma levels of FU and DHFU have demonstrated
a decreased ratio of FU to DHFU clearance after
MISO administration suggesting that MISO itself
may inhibit the initial catabolic step of FU
metabolism. However, the present study has
demonstrated a later onset of saturated kinetics of
renal clearance of total drug which is influenced by
MISO (Figure 1), indicating that an additional
mechanism of inhibition of FU clearance may be
implicated. Further studies are required to evaluate
the relative importance of MISO in inhibiting either
hepatic metabolism of FU or renal elimination of
parent drug and metabolites.
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